International Vaccine Institute
- Country
- 🇰🇷South Korea
- Ownership
- Private
- Established
- 1997-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.ivi.int
Hepatitis B Vaccine Delivered Trans-dermally by MAP
- Conditions
- Hepatitis B Vaccine
- Interventions
- Device: Hepatitis B Vaccine administered trans-dermally via Microneedle Array Patch (MAP)Biological: Active comparator vaccine via intramuscular injection
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- International Vaccine Institute
- Target Recruit Count
- 40
- Registration Number
- NCT06800131
Immunogenicity and Safety of Hecolin® in HIV Positive/Negative Adults and in Children
- Conditions
- Hepatitis E Virus Infection
- Interventions
- Biological: Hecolin® Recombinant Hepatitis E VaccineBiological: Isotonic Sodium Chloride injection
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- International Vaccine Institute
- Target Recruit Count
- 1040
- Registration Number
- NCT06306196
- Locations
- 🇿🇦
MeCRU Clinical Research Unit, Ga-Rankuwa, South Africa
🇿🇦Newtown Clinical Research Centre, Johannesburg, South Africa
🇿🇦Be Part Research, Paarl, South Africa
Global Burden Estimation of Human Papillomavirus (GLOBE-HPV)
- Conditions
- HPV Infection
- Interventions
- Other: Urine Sample CollectionOther: Self-collected Vaginal SwabOther: Blood Samples
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- International Vaccine Institute
- Target Recruit Count
- 29750
- Registration Number
- NCT06129253
- Locations
- 🇧🇩
Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh
🇬🇭University of Health and Allied Sciences (UHAS), Ho, Volta, Ghana
🇨🇩Institut National pour la Recherche Biomedicale (INRB), Kinshasa, Congo, The Democratic Republic of the
Safety and Immunogenicity of Hecolin® in Healthy Pregnant Women
- Conditions
- Hepatitis E Infection
- Interventions
- Biological: Hecolin® (Recombinant Hepatitis E Vaccine (Escherichia coli)).Other: Isotonic Sodium Chloride injection
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- International Vaccine Institute
- Target Recruit Count
- 2358
- Registration Number
- NCT05808166
- Locations
- 🇵🇰
The Aga Khan University, Karachi, Sindh, Pakistan
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar
- First Posted Date
- 2023-03-09
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- International Vaccine Institute
- Target Recruit Count
- 120
- Registration Number
- NCT05762393
- Locations
- 🇧🇫
Groupe de Recherche Action en Santé (GRAS), Ouagadougou, Burkina Faso
🇲🇬Madagascar Institute for Vaccine Research (University of Antananarivo), Antananarivo, Madagascar
TyVECO: Surveillance Protocol
- Conditions
- Intestinal PerforationTyphoid Fever
- First Posted Date
- 2022-09-30
- Last Posted Date
- 2022-09-30
- Lead Sponsor
- International Vaccine Institute
- Target Recruit Count
- 48000
- Registration Number
- NCT05562102
- Locations
- 🇨🇩
Nkandu 1 HC, Kisantu, Bas-Congo, Congo, The Democratic Republic of the
🇨🇩Kintanu Etat HC, Kisantu, Bas-Congo, Congo, The Democratic Republic of the
🇨🇩Nkandu 3 HC, Kisantu, Bas-Congo, Congo, The Democratic Republic of the
Dose Escalation Study to Evaluate the Safety and Immunogenicity of the Cholera Conjugate Vaccine in Healthy Adults
- Conditions
- Cholera Vaccination Reaction
- Interventions
- Other: Placebo Cohort AOther: Placebo Cohort BOther: Placebo Cohort C
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- International Vaccine Institute
- Target Recruit Count
- 150
- Registration Number
- NCT05559983
- Locations
- 🇰🇷
The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Republic of
🇰🇷CHA Bundang Medical Center (CBMC) of CHA University, Seoul, Korea, Republic of
🇰🇷Soon Chun Hyang University Hospital, Seoul, Korea, Republic of
Effectiveness Evaluation of the Sinopharm Vaccine in the Dondo District in Mozambique
- Conditions
- Sars-CoV-2 Infection
- Interventions
- Other: Sinopharm Vaccine
- First Posted Date
- 2022-05-05
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- International Vaccine Institute
- Target Recruit Count
- 3000
- Registration Number
- NCT05362682
- Locations
- 🇲🇿
Dondo Health Facility, Dondo, Mozambique
Effectiveness of a Typhoid Conjugate Vaccine in DRC
- Conditions
- Typhoid Fever
- Interventions
- Biological: Vi-TT
- First Posted Date
- 2021-11-15
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- International Vaccine Institute
- Target Recruit Count
- 48000
- Registration Number
- NCT05119426
- Locations
- 🇨🇩
CS Kavuaya, Kisantu, Bas-Congo, Congo, The Democratic Republic of the
🇨🇩CS Kimuisi, Kisantu, Bas-Congo, Congo, The Democratic Republic of the
🇨🇩CS Kintanu Etat, Kisantu, Bas-Congo, Congo, The Democratic Republic of the
Mix and Match Heterologous Prime-Boost Study Using Approved COVID-19 Vaccines
- Conditions
- Covid19
- Interventions
- Biological: BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell)Biological: Ad26.COV2.S (Recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein),Biological: Placebo - Normal saline (0.9% sodium chloride solution)
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- International Vaccine Institute
- Target Recruit Count
- 360
- Registration Number
- NCT04998240
- Locations
- 🇲🇬
Madagascar Institute for Vaccine Research (MIVR), University of Antananarivo, Antananarivo, Madagascar
🇲🇿Centro de Investigação e Treino em Saúde da Polana Caniço - Instituto Nacional de Saúde, Maputo, Mozambique